SarcopeniaNCT07244601
Case Control in Sarcopenia Among Elderly Type 2 Diabetic Patients
An observational study of Sarcopenia, run by Eman Alaa Eldean Mohamed.
Trial summary
1. Assess sarcopenia prevalence in elderly diabetic patients. 2. Evaluate impact of diabetes and its medications on muscle health. 3. detect effect of sacropenia on quality of life on elderly Read more about this study
- Who is it for?
- Ages 65 years and olderHealthy volunteers can take part
- Conditions the study is for
- Sarcopenia
- What is being tested?
- muscle ultrasound
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 22 Dec 2025to 20 Oct 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- Healthy volunteers accepted
- Older adult
Study population: 1. Inclusion criteria: The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes) ●Able to give informed consent 2. Exclusion criteria: * chronic renal disease * chronic liver disese * Severe cognitive impairment * Known neuromuscular diseases affecting mobility * malignancy Data of the study will collected over one year duration from 1/2026 _1/2027
- Inclusion criteria: The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes) ●Able to give informed consent
- Exclusion criteria:
- chronic renal disease
- chronic liver disese
- Severe cognitive impairment
- Known neuromuscular diseases affecting mobility
- malignancy Data of the study will collected over one year duration from 1/2026 _1/2027
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Asessment of Sarcopenia Among Elderly Type 2 Diabetic Patients
- Assess sarcopenia prevalence in elderly diabetic patients.
- Evaluate impact of diabetes and its medications on muscle health.
- detect effect of sacropenia on quality of life on elderly
- Conditions
- Sarcopenia
- Being tested
- muscle ultrasound
- Medical subject headings
- Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
muscle ultrasoundDiagnostic test
Bedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity
| Study group | Role | What they receive |
|---|---|---|
| Diabetic Group | Elderly patients with type 2 diabetes mellitus. Participants will be evaluated for the presence or absence of sarcopenia using muscle ultrasound and clinical criteria. Receives: Diagnostic Test: muscle ultrasound | |
| Non-Diabetic Group | Elderly patients without diabetes mellitus. Participants will also be assessed for sarcopenia using muscle ultrasound and standard diagnostic criteria. Receives: Diagnostic Test: muscle ultrasound |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of sarcopenia assessed by muscle ultrasound in elderly diabetic
Sarcopenia will be evaluated using muscle ultrasound to measure muscle thickness and echo intensity of the quadriceps muscle. The results will be interpreted according to EWGSOP2 diagnostic criteria, which combine muscle mass and muscle strength parameters
Measured: Within 6 months from the start of recruitment.
Assessment of muscle strength using handgrip dynamometry
Handgrip strength will be measured using a handheld dynamometer, and the average of three attempts for the dominant hand will be recorded.
Measured: Within 6 months
Secondary outcomes (1)
Quality of life score using the SarQoL questionnaire.
Quality of life related to sarcopenia will be evaluated using the validated SarQoL questionnaire.
Measured: Within 6 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2025
- Study start22 Dec 2025 (estimated)
- Primary completion20 Oct 2027 (estimated)
- Study completion20 Oct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Other
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eman Alaa Eldean Mohamed
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Eman Alaa Eldean Mohamed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07244601
- Sponsor's protocol ID
- sarcopenia in elderly diabetic
- Status last verified
- Dec 2025
- First submitted
- 23 Sep 2025
- Last updated
- 19 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Publications
Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F, Mei F, Zhao L, Ma B. Prevalence and Risk Factors of Sarcopenia in Patients With Diabetes: A Meta-analysis. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1470-1483. doi: 10.1210/clinem/dgab884.
PubMed 34904651
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Asessment of Sarcopenia Among Elderly Type 2 Diabetic Patients
- ClinicalTrials.gov ID
- NCT07244601
- Acronym / sponsor ID
- sarcopenia in elderly diabetic
- Conditions
- Sarcopenia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Eman Alaa Eldean MohamedUniversity, hospital or other
- Study start
- 22 Dec 2025 (estimated)
- Primary completion
- 20 Oct 2027 (estimated)
- Study completion
- 20 Oct 2028 (estimated)
- First posted
- 24 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Assess sarcopenia prevalence in elderly diabetic patients.
- Evaluate impact of diabetes and its medications on muscle health.
- detect effect of sacropenia on quality of life on elderly
Study design
- Observational model
- Case-control
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Diabetic Group | – | Diagnostic Test: muscle ultrasoundElderly patients with type 2 diabetes mellitus. Participants will be evaluated for the presence or absence of sarcopenia using muscle ultrasound and clinical criteria. |
| Non-Diabetic Group | – | Diagnostic Test: muscle ultrasoundElderly patients without diabetes mellitus. Participants will also be assessed for sarcopenia using muscle ultrasound and standard diagnostic criteria. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
- Study population
- 1. Inclusion criteria: The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes) ●Able to give informed consent 2. Exclusion criteria: * chronic renal disease * chronic liver disese * Severe cognitive impairment * Known neuromuscular diseases affecting mobility * malignancy Data of the study will collected over one year duration from 1/2026 _1/2027
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| muscle ultrasoundBedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity | Diagnostic test | Diabetic Group, Non-Diabetic Group |
Primary outcome
Prevalence of sarcopenia assessed by muscle ultrasound in elderly diabetic
Time frame: Within 6 months from the start of recruitment.
Sarcopenia will be evaluated using muscle ultrasound to measure muscle thickness and echo intensity of the quadriceps muscle. The results will be interpreted according to EWGSOP2 diagnostic criteria, which combine muscle mass and muscle strength parameters
Assessment of muscle strength using handgrip dynamometry
Time frame: Within 6 months
Handgrip strength will be measured using a handheld dynamometer, and the average of three attempts for the dominant hand will be recorded.
1 secondary outcome
Quality of life score using the SarQoL questionnaire.
Time frame: Within 6 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2025.
- Results publication: PubMed 34904651Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F, Mei F, Zhao L, Ma B. Prevalence and Risk Factors of Sarcopenia in Patients With Diabetes: A Meta-analysis. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1470-1483. doi: 10.1210/clinem/dgab884.
Related trials for Sarcopenia
Active, not recruiting
Group Exercise Program Supported By Audiovisual Media During Hemodialysis
Chronic Kidney Failure, Hemodialysis
Not yet recruitingEarly Phase 1
Sarcopenia in Chronic Kidney Disease (CKD) Patients
Chronic Kidney Disease, Sarcopenia
Not yet recruitingObservational study
CT Based Assessment of Sarcopenia and Its Association With Biologic Treatment Outcomes in Inflammatory Bowel Disease Patients
CT-Assessed Sarcopenia Outcomes
Enrolling by invitation
Exercise Intervention for Breast Cancer Patients With Sarcopenia
Sarcopenia, Breast Cancer
RecruitingObservational study
Sarcopenia and Training Outcomes in Post-cardiac Surgery Patients
Sarcopenia, Cardiac Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcopenia, run by Eman Alaa Eldean Mohamed.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact eman alaa eldean, master degree (2+01098614329, emanalaa359@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of sarcopenia assessed by muscle ultrasound in elderly diabetic (time frame: Within 6 months from the start of recruitment.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07244601, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2025; AzTrials last refreshed its copy on 3 Nov 2026.